Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Otolaryngology - Head and Neck Surgery, Amsterdam, the Netherlands; Department of Clinical, Neuro- and Developmental Psychology, Faculty of Behavioral and Movement Sciences & Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Otolaryngology - Head and Neck Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Oral Oncol. 2021 Oct;121:105505. doi: 10.1016/j.oraloncology.2021.105505. Epub 2021 Aug 27.
To investigate associations between testosterone and patient reported sexual problems and need for sexual care in head and neck cancer patients at time of diagnosis and 6 months after treatment.
Data and samples were used of 40 patients (20 men, 20 women) before and 6 months after treatment. Outcome measures were total testosterone level (TT) and free testosterone index (FTI), testosterone insufficiency (TI), the EORTC QLQ-HN35 Sexuality subscale, the subscales of the International Index of Erectile Function (IIEF), Female Sexual Function Index (FSFI), and the Sexuality subscale of the Short-Form Supportive Care Needs Survey (SCNS-SF34).
In men, higher FTI before treatment was significantly associated with better IIEF Orgasm (p = 0.020) and at 6 months follow-up with IIEF Desire (p = 0.019). Before treatment, insufficient testosterone was present in 5 males (25%) and in 3 at follow-up (15%) (2 patients who had TI before treatment plus one). In women, higher TT at follow-up was significantly associated with better EORTC Sexuality (p = 0.031) and FSFI Satisfaction (p = 0.020); FTI at follow-up was associated with FSFI Satisfaction (p = 0.012). Before treatment, TI was present in 2 women (10%) and in 3 (15%) at follow-up (the same 2 patients plus one).
This pilot study showed that testosterone seems to be associated with patient reported sexual outcomes among male and female head and neck cancer patients. It is estimated that 10-25% of HNC patients may have testosterone insufficiency before treatment and/or at 6 months after treatment.
调查诊断时和治疗后 6 个月时头颈部癌症患者的睾酮与患者报告的性问题和性护理需求之间的关系。
使用了 40 名患者（20 名男性，20 名女性）治疗前后的数据和样本。结局测量指标包括总睾酮水平（TT）和游离睾酮指数（FTI）、睾酮不足（TI）、EORTC QLQ-HN35 性生活子量表、国际勃起功能指数（IIEF）的子量表、女性性功能指数（FSFI）和简短支持性护理需求调查（SCNS-SF34）的性生活子量表。
在男性中，治疗前较高的 FTI 与更好的 IIEF orgasm（p=0.020）和治疗后 6 个月时的 IIEF 欲望（p=0.019）显著相关。治疗前，5 名男性（25%）和 3 名（15%）男性存在睾酮不足（2 名治疗前存在 TI 的患者加 1 名）。在女性中，治疗后较高的 TT 与更好的 EORTC 性生活（p=0.031）和 FSFI 满意度（p=0.020）显著相关；治疗后 FTI 与 FSFI 满意度相关（p=0.012）。治疗前，2 名女性（10%）和 3 名（15%）女性存在 TI（2 名治疗前存在 TI 的患者加 1 名）。
这项初步研究表明，睾酮似乎与男性和女性头颈部癌症患者的患者报告的性结果有关。估计有 10-25%的头颈部癌症患者在治疗前和/或治疗后 6 个月可能存在睾酮不足。
